Report From the NEI/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Diseases
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The Association for Research in Vision (ARVO), together with the Foundation Fighting Blindness (FFB), organized the National Eye Institute (NEI)–Food and Drug Administration (FDA) endpoints workshop on age-related macular degeneration (AMD) and inherited retinal diseases (IRD) on November 9, 2016. The public workshop convened basic researchers, clinicians, and regulatory authorities in an interactive forum to discuss the latest clinical findings on AMD and IRD with the goal of optimizing clinical trial design and developing trial endpoints. Specifically, the aim of the workshop was to assemble stakeholders from academic and regulatory spheres to discuss clinical data on potential primary and secondary clinical trial endpoints; patient stratification for disease monitoring, interventions, and evaluation of treatment response; and identification of future research avenues. The workshop was jointly organized by Dr. Frederick Ferris III, MD, Clinical Director at the NEI; Dr. Emily Chew, MD, Deputy Clinical Director at the NEI; Dr. Karl Csaky, MD, PhD, Managing Director and Head of Molecular Ophthalmology Laboratory at the Retina Foundation of the Southwest; Dr. Jacque L. Duncan, MD, Professor of Clinical Ophthalmology at the University of California, San Francisco; and Janet K. Cheetham, PharmD, from the FFB. The workshop format was a series of presentations followed by panel discussions, in which FDA representatives offered regulatory perspectives on potential endpoints for clinical trial design. The following key topics were discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In REFLECT, all eye groups, including placebo eyes, showed a statistically significant and clinically relevant improvement24 in mean LogMAR BCVA at 1.5 years versus nadir, similar to the bilateral response seen in both treated and sham eyes in REVERSE and RESCUE, and to a degree not reported in natural history studies of LHON patients of corresponding age and genotype.18”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [24]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamoureux, E. L., Pallant, J. F., Pesudovs, K., Hassell, J. B., & Keeffe, J. E. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0220 · Cited by 227 · cited 1×
“Dagnelie discussed a relatively modern mixed PRO, namely, the IVI questionnaire.(14) The content of this questionnaire has been validated by expert panel and focus groups, and it includes three domains: mobility and independence, emotional well-being, and reading and accessing information.”
BackgroundSchmitz-Valckenberg, S., Brinkmann, C. K., Alten, F., Herrmann, P., Stratmann, N. K., Göbel, A. P., Fleckenstein, M., Diller, M., Jaffe, G. J., & Holz, F. G. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-7457 · Cited by 201 · cited 1×
“Holz described semiautomated image processing software to detect and quantify such lesions.(1) Dr.”
MethodYehoshua, Z., Wang, F., Rosenfeld, P. J., Penha, F. M., Feuer, W. J., & Gregori, G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.05.008 · Cited by 190
Visual acuity as an outcome measure in clinical trials of retinal diseases
Beck, R. W., Maguire, M. G., Bressler, N. M., Glassman, A. R., Lindblad, A. S., & Ferris, F. L. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.06.047 · Cited by 188 · cited 1×
“percentage of success or failure between different treatment groups based on a specific number of lines on the scale.(8) Using mean changes requires smaller sample sizes in trials, increases precision, and helps avoid issues of misclassification around a”
BackgroundSelf-citationAbdelfattah, N. S., Zhang, H., Boyer, D. S., Rosenfeld, P. J., Feuer, W. J., Gregori, G., & Sadda, S. R. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-18572 · Cited by 167
Psychometric Properties of the Veterans Affairs Low-Vision Visual Functioning Questionnaire
Stelmack, J. A., Szlyk, J. P., Stelmack, T. R., Demers-Turco, P., Williams, R. T., Moran, D., & Massof, R. W. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0208 · Cited by 141 · cited 2×
“Dagnelie described a relatively modern Visual Function Questionnaire (VFQ) instrument, namely, the Veterans Administration Low Vision VFQ.(15) Dr.”
MethodRatnam, K., Carroll, J., Porco, T. C., Duncan, J. L., & Roorda, A. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-12557 · Cited by 109 · cited 1×
“Until approximately 50% of the cones were lost, visual acuity appeared to be relatively normal, decreasing below 20/25 after that threshold.(7) These findings suggest that combining AOSLO with other techniques such as SD-OCT, microperimetry, and visual acuity could increase the sensitivity of each technique for imagin…”
BackgroundSelf-citationA short-duration dark adaptation protocol for assessment of age-related maculopathy
Jackson, G. R., & Edwards, J. G. (2008) · Journal of Ocular Biology, Diseases, and Informatics · doi:10.1007/s12177-008-9002-6 · Cited by 108 · cited 1×
“Catherine Cukras discussed details of a study on dark adaptation in patients with various stages of AMD using a prototype of the AdaptDx device, which delivers an 80% focal bleach to a circular test spot on the retina located at 58 on the inferior visual meridian.(9) The study revealed that dark adaptation time tended…”
MethodLow-Luminance Visual Acuity and Microperimetry in Age-Related Macular Degeneration
Wu, Z., Ayton, L. N., Guymer, R. H., & Luu, C. D. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.02.005 · Cited by 106 · cited 1×
“3 letters in one study.(10) Independent analysis by different groups suggests that LLD measurements are reproducible and precise, as indicated by test–retest variability.”
BackgroundEye Tracking in the Wild: the Good, the Bad and the Ugly
Lappi, O. (2015) · Journal of Eye Movement Research · doi:10.16910/jemr.8.5.1 · Cited by 90 · cited 1×
“For example, stimuli in naturalistic tests are often rich and complex and include unlimited fields of view; tasks are often learned well before the experiment and embedded within natural behavior; and the behaviors entail unrestricted head and body movements and complex sequential actions.(13) Dr.”
Background
Cited by
Items 201–236 of 236
Boyer, D., Saad, L., Washington, I., Melamud, A., Graham, K. B., O’Malley, A. E., DeBartolomeo, G., Jiang, H. H., Harris, L. D., Kay, C. N., et al. (2026) · Ophthalmology Retina · doi:10.1016/j.oret.2026.05.018 · Cited by 1
Parimi, V., Elsner, A. E., Clark, C., & King, B. J. (2026) · PLoS ONE · doi:10.1371/journal.pone.0352879 · Cited by 1
Medikamentöse Therapieansätze für die nicht neovaskuläre AMD
Zeitz, O., Frentzel, D. P., Rübsam, A., Seibel, I., Riechardt, A. I., Brockmann, C., Meißner, F., & Joussen, A. M. (2019) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-0914-3183 · Cited by 1
“[30] Csaky K, Ferris F 3rd, Chew EY et al.”
BackgroundGene Therapy, Diet and Drug Approaches to Treating Inherited Retinal Disease
Simunovic, M. P., Mack, H. G., Ayton, L. N., & Hassall, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00154-7 · Cited by 3
Ichhpujani, P., & Thakur, S. (2024) · touchREVIEWS in Ophthalmology · doi:10.17925/usor.2024.18.1.5 · Cited by 1
“37 However, the relationship between CS and quality of life suggests that the benefits of treatment may be underestimated if CS is not considered.”
Rodriguez-Martinez, A. C., Tailor, V., Higgins, B. E., Jones, P. R., Dekker, T. M., Henderson, R., Greenwood, J. A., & Moosajee, M. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.5.32 · Cited by 1
“13 16 To further explore functional endpoints, it is essential to first gain a comprehensive understanding of the visual deficits and then incorporate newly designed, child friendly tests to improve the accuracy of monitoring of disease progression in the pediatric populations.”
Vingopoulos, F., Stevanovic, M., Razavi, P., Romano, F., Ding, X., Rodriquez, J., Baldwin, G. E., Choi, H., Katz, R., Husain, D., et al. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101206 · Cited by 1
“10 Among the functional metrics that have been gaining traction for AMD, contrast sensitivity (CS) shows good promise.”
Lessons From Rare Disease and Gene Therapy Clinical Studies in Ophthalmology
Spittal, N. (2021) · Springer eBooks · doi:10.1007/978-3-030-78605-2_14
Gene therapy and treatment trials
MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-813944-8.00008-1
A szemészeti génterápiák fejlődése : Pontszerző, továbbképző közlemény tesztkérdésekkel
Szabó, V., Varsányi, B., & Nagy, Z. Z. (2023) · Szemészet · doi:10.55342/szemhungarica.2023.160.4.154
Schmidt-Erfurth, U. M., & Riedl, S. (2024) · Die Ophthalmologie · doi:10.1007/s00347-024-02039-z
Qin, L. G., Pierce, M., Kasetty, V. M., Espinosa‐Heidmann, D. G., & Marcus, D. M. (2024) · touchREVIEWS in Ophthalmology · doi:10.17925/usor.2024.18.1.6
The BRIDGE Study Group, Sivaprasad, S., Loewenstein, A., Carneiro, Â. M., Midena, E., Bandello, F. M., Terheyden, J. H., Korobelnik, J., Zarranz‐Ventura, J., Viola, F., et al. (2025) · Eye · doi:10.1038/s41433-025-03832-z
“It was noted that FDA accepts anatomical endpoints for ophthalmological products when a clear relationship between structural and functional endpoints is established, as outlined in its specific guidance [6, 7].”
Anders, P., Anders, L.-M., Santos, A. R., Marques, I. P., Almeida, A. C., Futterknecht, S., Pfau, M., Hatz, K. B., Cunha-Vaz, J. G., Scholl, H. P. N., et al. (2025) · Ophthalmic Research · doi:10.1159/000546990
“Therefore, regulatory agencies have stressed the importance of functional metrics for assessing therapeutic interventions [5, 6].”
Shen, L. L., Zhang, Y., Wong, J., Foote, K. G., Porco, T. C., Wang, R. K., Roorda, A., & Duncan, J. L. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.11.40
“48 Based on our longitudinal data, if total macular sensitivity is used as the primary metric, the decline rate of 0.76 dB/year suggests that it would take approximately 9.2 years to reach a 7-dB loss.”
InfluentialSelf-citationBEYOND AREDS2: NEXT-GENERATION NUTRITIONAL SUPPLEMENTS FOR AGE-RELATED MACULAR DEGENERATION
Ćwiek, M., Omidi, A., Krawiec, B., Zarębski, B., Jadanowski, O., Sójka, J., Szombara, M., Mokrzyński, M., Szyszka, P., & Malec, K. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3710
Taylor, L. J., Josan, A. S., STRATTON, I. M., Jolly, J. K., & MacLaren, R. E. (2023) · Figshare · doi:10.6084/m9.figshare.23167613
Cinque, F., Pas, J. A. A. H., de Breuk, A., Heesterbeek, T. J., Klaver, C. C. W., Hoyng, C. B., Lechanteur, Y. T. E., & Heugten, C. M. V. (2026) · Translational Vision Science & Technology · doi:10.1167/tvst.15.2.5
Mukherjee, S., Chew, E. Y., Keenan, T. D. L., Lu, Z., Sherif, N., Arunachalam, T., Duic, C., Prasad, M., Siddig, F., Saroya, J., et al. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101110
Self-citationIbukun, F. A., Strauss, R. W., Rustam, Z., Khan, M. J., Cideciyan, A. V., Birch, D. G., Ho, A., Sunness, J. S., Audo, I. S., Michaelides, M., et al. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.3.6
“14 In particular, in addition to evidence of cross-sectional structure–function correlations, longitudinal data demonstrating the relationships between structural changes and “a future clinically significant outcome” also play an important role in regulatory considerations of structural endpoints.”
Goyal, S., & Vanita, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43986-5.00042-4
Multimodal imaging determinants of contrast sensitivity loss in geographic atrophy
Romano, F., Stettler, I., Finn, M. J., Vingopoulos, F., DING, X., Overbey, K. M., Cort, T., Chen, C., Ploumi, I., Baldwin, G. E., et al. (2026) · British Journal of Ophthalmology · doi:10.1136/bjo-2025-329036
“7 Second, our findings provide hypothesis-generating insights into the spatial characteristics of photoreceptor dysfunction in AMD.”
Zhou, L., White, E., Matteson, A., Andrews, A., Bailey, S. T., Lujan, B. J., Jia, Y., Huang, D., & Chen, S. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101250
“10,11 While electroretinography provides direct measurements of the photoreceptor electrophysiology, its use in routine clinics is limited by substantial logistical burden.”
Tandon, N. R., Vasquez, E., & Csaky, K. G. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101267
“13,14 Cone photoreceptors are concentrated in the central 1 mm of the fovea, enabling sharp color vision under photopic (well-lit) conditions.”
Self-citationPyramid-based Bayesian modeling for high-resolution behavioral analysis
Lu, Z. (2026) · Journal of Vision · doi:10.1167/jov.26.7.2
Elsner, A. E., Parimi, V., Clark, C., Walker, B. R., King, B. J., & Fawzi, A. (2026) · Biomedical Optics Express · doi:10.1364/boe.603037
Comparison of Measurement Techniques for Photoreceptor Loss in Geographic Atrophy
Schulz, M., Macha, N. N., Zhang, S., Pak, J. W., Storm, S., Lopez, D. A., Blodi, B. A., & Domalpally, A. (2026) · Translational Vision Science & Technology · doi:10.1167/tvst.15.7.8
Von Phase I bis IV – Studiendesigns in der Ophthalmologie richtig verstehen und bewerten
Pfau, K., Deutsch, A., Németh, R., Fuhrmann, C., & Holz, F. G. (2026) · Die Ophthalmologie · doi:10.1007/s00347-026-02474-0
Futterknecht, S., Pfau, M., Hall, U., Gabrani, C., Anders, P., Ansari, G., Traber, G. L., Scholl, H. P. N., Feltgen, N., Herzog, M., et al. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101351
“22 In this context, spatial-frequency — specific functional testing may help refine characterization of early retinal dysfunction before overt visual acuity loss occurs.”
Trinco, A., Nardi, C., D'Introno, R., Bosello, F., Casati, S., Zaffalon, C., Bertoni, A. I., Medori, M. C., Bertelli, M., Cozzi, M., et al. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101383
“13,15 The experience from recent complement — inhibition trials in GA has high-lighted the need for sensitive, anatomically aligned functional measures capable of detecting meaningful change.”
Bianco, L., Forte, G., Antropoli, A., Fabbro, S. D., Doddato, G., Calzavara, S., Scalabrin, G., Toscani, R., Melenchi, R., Pina, A., et al. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.11.1
“Notably, sensitivity thresholds for clinically meaningful progression proposed by FDA 34 and possibly accepted as endponts for trials were not reached by any eye with BVMD in our cohort at either two or four years.”
Birner, K., Mai, J., Boryshchuk, D., Frommlet, F., Schwartz, R., Schürer‐Waldheim, S., Leingang, O., Dieter-Vogl, W., & Schmidt-Erfurth, U. M. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.11.28
Taylor, L. J. (2026) · City Research Online (City University London)
Krawczynski, M. R., Everdingen, J. V., Leroy, B. P., Verny, C., Bauer, N. J. C., Andris, C., Lorenz, B., Votruba, M., Priglinger, C., Jurkutė, N., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-14181-6
Integration of biomarkers in common retinal neurodegenerative diseases: a comprehensive review
Fazal, Z. Z., Stroumza, J. R., Patel, S. H., Uy, F. R. C., Ali, H., Khan, H., Goldberg, J. L., & Sepah, Y. J. (2026) · Mammalian Genome · doi:10.1007/s00335-026-10282-9
“…EZ loss and point-wise microperimetric sensitivity as potentially acceptable endpoints where their relationship to visual function is established (Csaky et al. 2017), but none of these biomarkers has yet served as the primary basis for regulatory approval, and their routine clinical use remains…”
Raji, S., Taylor, L. J., & MacLaren, R. E. (2026) · Ophthalmic and Physiological Optics · doi:10.1007/s44402-026-00217-x
Metadata
- Authors
- Csaky, K., Ferris, F., Chew, E. Y., Nair, P., Cheetham, J. K., & Duncan, J. L.
- Affiliations
- Retina Foundation of the Southwest (US)
- National Institutes of Health (US)
- Washington, District of Columbia, United States
- Foundation Fighting Blindness (US)
- University of California, San Francisco (US)
- Corresponding author
- Duncan, Jacque L.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2017-07-21
- Volume
- 58
- Issue
- 9
- Pages
- 3456
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- PMC
- PMC5961066
- OpenAlex
- W2735396028
- Cited by
- 231
- References
- 15
- Citations by year
- 2026: 22 · 2025: 38 · 2024: 40 · 2023: 28 · 2022: 26 · 2021: 28 · 2020: 25 · 2019: 15 · 2018: 8 · 2017: 1
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- age-related macular degeneration, inherited retinal disease, clinical trial endpoints, visual function outcomes, retinal degeneration
- MeSH terms
- Clinical Trials as Topic, Humans, Macular Degeneration, Retinal Diseases, Visual Acuity, Visual Fields, Endpoint Determination, Geographic Atrophy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.